Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation load increases the likelihood that immunogenic neoantigens expressed by tumor cells may induce a response to immunotherapy.  However, TMB estimation and reporting can be heavily influenced by differing working processes across clinical and research laboratories; primarily, the choice of assay, platform, and how the assay is implemented and interpreted. To streamline and standardize this process at scale, QIAGEN offers an end to end solution, from detection to interpretation of TMB and other somatic alterations.

In this webinar, we will provide insights into the implementation of the QIAseq Tumor Mutational Burden (TMB) Panel in the molecular diagnostics lab. This comprehensive cancer panel is capable of interrogating TMB, microsatellite instability (MSI), and other actionable alterations in a single assay, using specialized chemistry to remove false positives. Subsequently, we will discuss how QIAGEN Clinical Insight Interpret can streamline insights from comprehensive cancer profiles to deliver actionable information on detected variants and immunotherapy biomarkers, such as tumor mutational burden (TMB) and microsatellite instability (MSI). We will also discuss the concordance of the automatic implementation of the AMP/ASCO/CAP guidelines with manual expert classifications.